Objectives-To determine the probability of drug continuation in a large cohort of methotrexate treated rheumatoid arthritis (RA) patients, the reasons for discontinuation of methotrexate, the overall survival of the members of this cohort, and the causes of death in these patients. Methods-Yearly follow up was conducted in methotrexate treated RA patients who formed a cohort between 1981 and 1986 at a tertiary care centre. The probability of drug continuation and the patients' survival were calculated using standard statistical procedures; standardised mortality ratios were calculated using death certificate data and USA general population and mortality tables. Results-The probability of methotrexate continuation at 10 years from the time the first members entered the cohort was 30%. Toxicity (and its severity) was the most frequent cause of discontinuing methotrexate. The cumulative probability of survival was 85% for women and 45% for men. A greater than expected number of deaths from infections was observed, but the number of deaths from cancer and cardiovascular diseases were within the range expected.
Abstract
Objectives-To determine the probability of drug continuation in a large cohort of methotrexate treated rheumatoid arthritis (RA) patients, the reasons for discontinuation of methotrexate, the overall survival of the members of this cohort, and the causes of death in these patients. Methods-Yearly follow up was conducted in methotrexate treated RA patients who formed a cohort between 1981 and 1986 at a tertiary care centre. The probability of drug continuation and the patients' survival were calculated using standard statistical procedures; standardised mortality ratios were calculated using death certificate data and USA general population and mortality tables. Results-The probability of methotrexate continuation at 10 years from the time the first members entered the cohort was 30%. Toxicity (and its severity) was the most frequent cause of discontinuing methotrexate. The cumulative probability of survival was 85% for women and 45% for men. A greater than expected number of deaths from infections was observed, but the number of deaths from cancer and cardiovascular diseases were within the range expected. Demographic and clinical data were ascertained by chart review, and severity of disease was graded on the four point scale (both used previously2): 1 = mild; 2 = moderate; 3 = severe; 4 = very severe. This score includes different permutations of three (weighted) measures: function (determined by the ARA functional class), anatomy (scoring hand/wrist radiographs), and presence (and number) of extra-articular manifestations (clinical assessment of anaemia, nodules, serositis, pulmonary involvement, vasculitis).
Conclusions-Toxicity remains the most
Data regarding MTX intake, MTX discontinuation, reasons for MTX discontinuation, and the occurrence of side effects and their severity, were obtained on a yearly basis by both chart review and a telephone interview conducted by an experienced research assistant (ICT). As before, a major toxic event was defined a priori as one that was potentially life threatening, whereas a minor side effect was defined as one which was not. For those patients in whom MTX had been permanently discontinued, the yearly record was limited to the patient's survival. Causes of death were identified using death certificates for the Alabama Department of Vital Statistics for all but one patient, who died in another state and Survival and drug discontinuation analyses in methotrexate treated rheumatoid arthritis patients The Kaplan-Me estimate the overaL these patients;6 th4 with data available i e of death was ascertained is. The status of all patients at the time of the last yearly determining the probability n or discontinuation (rather val), the time on MTX was ime since MTX was first Le at the last follow up visit; three months of discon-USA actuarial data for a population with the same characteristics for age, gender, and race (no figures are available for the state of Alabama).'3 Standardised mortality ratios (SMRs) were calculated (observed number of deaths v expected number of deaths) on the basis of race, gender, age, calendar year, and cause specific mortality rates for the USA population.'4 The expected number was calculated by multiplying the USA rate by the number of person-years of follow up accrued by the cohort in each category of race, gender, age, and calendar year (five year categories). Observed and expected deaths were also cross classified by duration of treatment (one year categories) and time since onset of the disease (five year categories). SMRs and their 95% confidence intervals (CI) are reported. Hypothesis testing and interval estimation procedures pertaining to the SMR analyses are based on the assumption that the observed number of deaths followed a Poisson distribution.' 5 16 were subtracted from the Results Le intake. A patient discon-MTX ADMINISTRATION greater period of time was Table 1 shows the baseline demographic and ing discontinued the drug clinical data of the RA patients studied. At the time of the present follow up study, the mean s of MTX discontinuation (SD) duration, weekly dose, and cumulative rt and for different subsets dose for those patients still taking MTX re ascertained using the were 80-4 (20.2) months, 13-6 (7-1) mg and ell and Shulman.4 The 4741-7 (2684-4) mg, respectively; for those .e or discontinue MTX was no longer taking MTX, the values were t's treating rheumatologist (25-1) months, 10-2 (7-5) mg, and ria defined a priori. Differ-1358-5 (1875-9) mg, respectively. The differse probability curves were ences between the mean weekly doses of MTX ethod of Greenwood.5 One for the two groups was not statistically signifi-;ed for variables previously cant but, as expected, there were differences icant predictors in the five between the mean cumulative doses and rwise two sided tests were duration ofMTX administration for patients in as considered significant. the two groups. Ninety four patients had I as significant in the uni-discontinued MTX permanently whereas 58 vere entered into a Cox were still taking it, giving an overall cumulative n order to determine their probability of MTX continuation at 10 years nt predictors of drug con-of approximately 30% (fig 1) . The probability tinuation.
was 23 for the remaining discontinuations (33%); they Time (years: Figure 1 Cumulative probability ofcontinuing to take , rheumatoid arthritis patients. tNumber ofpatients remai I'---,
_--_ Discussion (26) Methotrexate has become the disease modi- Survival and dnrg discontinuation analyses in methotrexate treated rheumatoid arthritis patients Table 4 Observed and expected number ofdeaths*, standardised mortality ratio (SMR), and 95% confidence interval (CI) large enough for such an event to have occurred or been detected. Other reasons for discontinuing MTX, such as lack of efficacy of intervening surgery, occurred with frequencies comparable to those of the analyses at five years. Because of our initial negative experience with the use of MTX through surgery, most surgeons at our institution required that MTX be withheld before and after surgery;28 in some of these patients, MTX was never restarted, as the disease appeared not to flare.
In order to be able to compare the 10 year data with our previously published five year data, we chose the year 1984 as a reference against which to examine the impact of year (early v late) at which MTX had been initiated. This parameter, which was an independent predictor of MTX discontinuation in the five year analyses, failed to reach significance at 10 years, which suggests that, for both patients and physicians, the learning curve for use of MTX had been completed. Favouring this assertion also is the fact that there were only a few MTX discontinuations because of minor side effects at 10 years, in contrast to our experience at five years (data not shown). Finally, the proportion of patients who permanently discontinued the drug because of its lack of efficacy remained relatively small, but a variety of medical and non-medical events accounted for a number of discontinuations. As changes in MTX regimens were instituted by each patient's primary rheumatologist, we have not attempted to measure the efficacy of the drug over time; as noted, our data cannot be directly compared with those obtained in long term prospective cohort studies in which efficacy was assessed using structured protocols.29 34 Our patients (both men and women) experienced a decreased probability of 
